Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.DIABRES.2006.07.019PMID 17069922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.

  2009cited by this paper
• Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system.

  2006cited by this paper
• Mechanisms of insulin resistance caused by nutrient toxicity.

  2005cited by this paper
• Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets

  2005cited by this paper
• Risk factors for worsening to diabetes in subjects with impaired glucose tolerance

  2004cited by this paper
• Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies.

  2004cited by this paper
• Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes.

  2004cited by this paper
• Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes

  2004cited by this paper
• Consequences on beta-cell function and reserve after long-term pancreas transplantation.

  2004cited by this paper
• Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection.

  2003cited by this paper
• β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

  2003cited by this paper
• In search of normoglycaemia in diabetes: controlling postprandial glucose

  2002cited by this paper
• Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.

  2002cited by this paper
• Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

  2002cited by this paper
• Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.

  2002cited by this paper
• In search of normoglycaemia in diabetes: controlling postprandial glucose

  2002cited by this paper
• The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes

  2001cited by this paper
• Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

  2001cited by this paper
• Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

  2001cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

  2000cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration.

  1998cited by this paper
• Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Modification of Postprandial Hyperglycemia With Insulin Lispro Improves Glucose Control in Patients With Type 2 Diabetes

  1997cited by this paper
• Improving Insulin Therapy: Achievements and Challenges

  1994cited by this paper
• The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles.

  1994cited by this paper
• Improving insulin therapy: achievements and challenges.

  1994cited by this paper
• Differentiating Glucose Toxicity From Glucose Desensitization: A New Message From the Insulin Gene

  1994cited by this paper
• Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic Alpha cells

  1991cited by this paper
• Perfect Normalization of Excessive Glucagon Responses to Intravenous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell

  1980cited by this paper
• Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon

  1977cited by this paper
• C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus

  1977cited by this paper
• Joslin's Diabetes Mellitus

  1971cited by this paper

• Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study

  2020cites this paper
• Chinese men living in urban areas of Shijiazhuang, Hebei at higher risk of overweight or obesity

  2020cites this paper
• Systematic estimation of BMI

  2019cites this paper
• Associations among Obesity, Eating Speed, and Oral Health

  2018cites this paper
• Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes

  2018cites this paper
• Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study

  2015cites this paper
• Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.

  2012cites this paper
• Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver.

  2012cites this paper
• Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.

  2012cites this paper
• Pharmacokinetics and pharmacodynamics of insulin aspart in patients with Type 2 diabetes: Assessment using a meal tolerance test under clinical conditions

  2012cites this paper
• Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.

  2008cites this paper
• Current literature in diabetes

  2007cites this paper
• Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes.

  2007cites this paper